癌症免疫疗法反应和抵抗的转录决定因素。
Transcriptional determinants of cancer immunotherapy response and resistance.
机构信息
Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35233, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
出版信息
Trends Cancer. 2022 May;8(5):404-415. doi: 10.1016/j.trecan.2022.01.008. Epub 2022 Feb 3.
The host immune response is a potent defense mechanism against cancer development and progression. To survive, cancer cells must develop mechanisms to evade the immune response. Based on this knowledge, a series of new therapies collectively referred to as immunotherapies have been developed and translated to the clinic for treating cancer patients. Although some cancer subtypes have shown strong clinical responses, including curative outcomes in some patients, immunotherapies have not worked as desired for some subtypes and forms of cancers. We provide an overview of the transcriptional mechanisms that drive the response and resistance to immunotherapies. We also discuss possible interventions to enhance the outcomes of immunotherapies by targeting dysregulated transcriptional networks in cancer cells.
宿主免疫反应是对抗癌症发生和发展的强大防御机制。为了生存，癌细胞必须发展逃避免疫反应的机制。基于这一知识，一系列新的治疗方法被统称为免疫疗法，并已转化为临床，用于治疗癌症患者。尽管一些癌症亚型显示出强烈的临床反应，包括一些患者的治愈结果，但免疫疗法对一些亚型和形式的癌症并没有达到预期的效果。我们提供了一个概述，介绍了驱动免疫疗法反应和抵抗的转录机制。我们还讨论了通过靶向癌细胞中失调的转录网络来增强免疫疗法结果的可能干预措施。
Zotero 插件